Table 4 Odds ratios for Kaposi's sarcoma among those with two serum samples available for testing, according to whether the first and second sample was sero-positive or negative for latent and lytic anti-KSHV antibodies

From: A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein–Barr virus in adults with human immunodeficiency virus-1

 

Latent antibodies

Lytic antibodies

1st sample/2nd sample

Number of cases/controls N =118

OR (95% CI)

Number of cases/controls N =116

OR (95% CI)

neg/neg

56/89

1.0

71/92

1.0

neg/pos

15/16

1.5 (0.6–3.5)

16/7

3.8 (1.4–10.0)

pos/neg

15/4

9.6 (2.1–43.5)

17/8

2.7 (1.2–6.0)

Pos/pos

32/9

5.5 (2.6–11.6)

12/9

2.2 (0.9–5.1)

  

χ 2 (3)=27.9, P<0.001

 

χ2(3)=11.0, P=0.01

Back to article page